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Over the last decade progress has been made 
leading to the discovery of hundreds of small non-
coding RNAs (ncRNA). A fraction of these non-
coding transcripts was denoted as microRNAs 
(miRNAs) due to their ~ 22-nucleotide size. miRNAs 
expression was demonstrated to be tightly regulated 
during development. This class of ncRNAs is highly 
conserved in both plants and animals. The most 
original miRNAs to be discovered, lin-4 and lin-7 
in Caenorhabditiselegans (c.elegans), were found to 
have critical roles in controlling development timing, 
by regulating mRNA translation. High level of lin-4 
up-regulation takes place during the transition from 
the first to the second larval stage (L2), whereas it 
occurs for lin-7 from the forth-larval (L4) stage to the 
adult (1,2).
miRNAs regulate hundreds to thousands of protein 
coding genes by post-transcriptional gene silencing 
in animals and plants (3). These non-coding RNAs 
principally target the 3'-untranslated region (UTR) 
of genes. However, other reports have also shown 
that miRNAs can also target the 5'- untranslated re-
gion and coding region of their target-mRNA (3). 
The fine-tuning of proteins expression via miRNAs 
miR-218 as a Multifunctional Regulator of Oncogenic 
Processes in Diﬀerent Solid Tumors
Fereshteh Ahmadinejad1, Mohammad Amin Honardoost 2 , Seyed Javad Mowla3, Hossein Teimori1   , Kamran Ghaedi2
1. Cellular and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
2. Division of Cellular and Molecular Biology, Department of Biology, Faculty of Sciences, University of Isfahan, Isfahan, Iran 
3. Molecular Genetics Department, Faculty of Biological Sciences, TarbiatModarres University, Tehran, Iran
* Kamran Ghaedi, PhD
Associate Professor of Genetics. Department of Biology, School of 
Sciences, University of Isfahan, Iran
Email: Kamranghaedi@sci.ui.ac.ir
* Hossein Teimori, PhD
Cellular and Molecular Research Center, Shahrekord University of Medi-
cal Sciences, Shahrekord, Iran
hosseintimm@yahoo.com
Submission Date: 24 Jun. 2015  Acceptance Date: 8 Oct. 2015
Review Article
Abstract
microRNAs are highly conserved small non-coding regulatory RNAs that involve in post transcriptional regu-
lating of gene expression during different cellular mechanisms. Aberration of miR-218 expression during tum-
origenesis of different solid tumors has been reported by numerous studies. In current systematic review arti-
cle, by using the terms “miR-218” and “cancer” we first searched for English language articles in the PubMed 
database, published from 1993 to April 2014. Then by a comprehensive review of related articles, we provided 
some new insights that highlight novel features and functions of miR-218 in initiation and progression of solid 
tumors. The majority of these studies propose a tumor suppressing role for miR-218 considering the fact that it 
is significantly down-regulated in tumor tissues compared with normal specimens. Despite accumulating body 
of evidence regarding tumor suppressor functions of miR-218 in solid tumors; more intensive reviewing about 
available miR-218 recent original studies and interpretation of existing data, revealed the multifunctional role 
of miR-218 in these kinds of malignancies by targeting different corresponding target genes. Take all together, 
MiR-218 targets different cellular processes in cancer cells and its expression pattern is in an important asso-
ciation with various states and features of tumors. It seems that miR-218 can increase the speed of cell cycle 
and cell division in lower sample grades and along with progression of cancer cells it's function changes to 
stabilization the cancer cells and not allowing them to invade. thats why it often shows up-regulation in lower 
grades and down-regulation in metastatic phase. Therefore, it seems of great importance to check samples 
stage, grade, lymph node metastasis status and other tumor features before evaluation of miR-218 as a prog-
nostic or diagnostic biomarker.
Key words: Biomarkers; Cancer; microRNA
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can change the yield of proteins in eukaryotic cells, 
thus influencing the whole networks and pathways. 
Computational studies have revealed that miRNAs 
control their target-genes expression through seed re-
gion, ~8 nt at the 5’ end, which is crucial for miRNA 
functioning (4). 
Several studies in model organisms have 
shown that miRNAs are involved in regulating 
development timing, proliferation, morphogenesis, 
and apoptosis (5). Given the importance of this class 
of ncRNAs, some lines of evidence have directly 
linked their aberrant expression and function to the 
development of several pathological conditions (6-
8) and carcinogenesis (9). These studies indicated 
that miRNAs could function as classical tumor 
suppressors and/or oncogenes (10-12). MiR-218 
has all the earmarks of being a vertebrate particular 
microRNA and has now been affirmed in an 
extensive variety of vertebrate species. According to 
Lorenzo F Sempere et al. report miR-218 first found 
to reduce Lin-218 expression level in mouse P19 
cell lines through neural differentiation. Additionally 
they identified conserved predicted binding sites in 
mammalian lin-8 3-UTR messenger RNAs (13). 
MiR-218 could provide invaluable. information to 
analysis of human disease and it is nearly connected 
with different malignancies. Associations between 
miR-218 expression and clinicopathological feature 
of different cancer samples reported by numerous 
studies (14-16). Circulating miR-218 represents 
potential biomarker for early diagnosis and 
prognosis of kidney cancer, esophageal squamous 
cell carcinoma, esophageal cancer, glioma and 
hepatocellular carcinoma (17-21).
Previously performed expression signature 
studies demonstrated that miR-218 is under-
expressed in various types of human cancers, 
including esophageal, cervical, lung squamous cell 
carcinomas, hypopharyngeal, maxillary sinus, in 
addition to bladder cancer and renal cell carcinomas. 
Recent functional studies indicated that miR-218 acts 
as a tumor-suppressor miRNA through inhibiting 
cancer cells proliferation and invasion, via targeting 
oncogenic genes (14, 22-25). On the other hand, 
other studies confirmed that miR-218 is up-regulated 
in pancreatic cancer (26) resulting in controversial 
attitude toward precise molecular role of miR-218 in 
different types of cancer. 
In current review, first we have provided a brief 
summary of miRNA biogenesis and mechanisms 
of their deregulation during malignances. Then, by 
providing a comprehensive literature mining of the 
studies representing oncogenic or tumor suppressor 
role of miR-218, we seek to delineate the precise 
molecular function of miR-218 in various types of 
cancer and resolve controversial ideas about it. We 
will also discuss overall opinions about the possibility 
of employing miR-218 as a diagnostic/prognostic 
biomarker. We preferentially selected articles with 
mechanistic data supporting expressional findings 
on the role of miRNA-218 in several human cancers 
namely cervical, breast, brain, pancreatic, gastric, 
liver, prostate and lung squamous cell cancer.
 
Method: 
Literature search
On February 1, 2015, we search Pubmed 
repository for a detailed literature linking between 
miR-218 and human cancers. The following key 
words were utilized: miR-218 OR miRNA-218 
OR microRNA-218 AND cancer OR tumor OR 
malignancy AND cervical OR breast OR lung 
squamous cell cancer OR brain OR pancreatic OR 
gastric OR liver OR prostate. 
Literature selection 
English-written reports, with sufficient scientific 
details, as well as with extraordinary novelty were 
selected. We preferentially selected articles with 
mechanistic data supporting expressional findings. 
We mined full reports and searched their references 
for relevant missing manuscripts.
 
Literature Synthesis
Our literature search retrieved 160 manuscripts. 
We selected 124 that were of sufficient reporting 
rigor or novelty. We mainly employed articles that 
revealed mechanistic data about miR-218 function in 
different human cancers. Additionally, we excluded 
non-human studies as well as polymorphism reports.
Introduction To MiR-218
MiRNA biogenesis and function
The maturation of 20-23 nt miRNA molecules 
involves a multi-step excision process of the primary 
miRNAtranscript (pri-miRNAs) containing one or 
more 70 nt hairpin miRNA precursors (pre-miRNA). 
Pri-miRNA itself may vary in size from 100 bp 
to more than 10 kb, and they may have their own 
promoters or share promoters with other coding 
genes. The Primary transcripts might also contain 
polycistronically-arranged miRNAs, introns and 
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exons of protein coding genes (27). In the nucleus, 
these hairpin structures are recognized by a double 
stranded RNA-binding protein called DGCR8 as 
well as by an RNAseӏӏӏ molecule known as Drosha, 
and excised to produce pre-miRNAs. Subsequently, 
pre-miRNAs are transported via exportin 5 (XPO5) 
to the cytoplasm, to be processed furthermore by 
Dicer complex, containing DICER1, dsRPBs (TRBP 
and/or PRKRA), to yield an RNA intermediate 
duplex, comprising the mature miRNA and miRNA* 
sequences. While miRNA sequence is loaded into 
miRNA-containing ribonucleoprotein complex 
(RBPs), known as miRNA-induced silencing complex 
(miRISC), miRNA* is released and degraded. 
miRISC contains a member of Argonate/EIF2C 
protein family (Ago2) that is responsible formiRNA 
binding and target mRNA recognition. Moreover, 
other RBPs are associated with miRNA biogenesis, 
including DHX9, DDX6, MOV10, DDX5, DDX17, 
LIN28A, HNRNPA1 and KSRP (28). MiRNAs 
can be modified subsequently following their 
transcription by several enzymes; they can be edited 
by deaminases, or pre-miRNAs may be uridylated by 
uridyltransferases. These modifications may affect 
the sequences of miRNA and miRNA*, or their 
amount and ratio (29,30). 
Several reports have indicated that a subset of 
miRNAs bypass the universal miRNA maturation 
order and their trimming can be independent of 
DGCR8 and Drosha, or are DICER1-independent 
(31-33), such as miR-320/miR-484 and miR-451 
respectively. 
Micro-RNAs do not act as naked RNAs;instead, 
they function as effector complexes, through 
recruiting members of miRIS Capparatus.The mature 
miRNA molecule incorporated within the complex, 
determines the fate of mRNA-target molecule. As 
mentioned previously, miRNA binds through its 6mer 
to 8mer seed sequence to the 3’UTR of the mRNA 
molecule. The nature of miRNA-target mRNA 
complementarity determines the fate of the mRNA; 
complete complementarity drives the mRNA to 
degradation, whereas incomplete matching prevents 
the translation of mRNA (28).
 
MiRNAs deregulation in cancer
miRNAs comprise 1-2% of all genes in different 
organisms; including mammals (3), and it is 
predicted that every miRNA regulates hundreds of 
target genes, making regulating protein coding genes 
their major objective (34). Hence, every biological 
process is subjected to miRNA dependent regulation. 
Mostly the physiological functions of miRNAs 
were deduced through overexpression studies in 
both model organisms and cell lines, and through 
antisense-molecules mediated knock down of the 
target miRNAs. These experiments  have assigned 
crucial regulatory roles to miRNAs in processes such 
as cell proliferation, differentiation and survival, and 
have attributed them as vital players during normal 
development, homeostasis, and disease (11,35-38).
The aberrant miRNA expression may happen 
as consequence of genetic loss or gain (39), 
epigenetic silencing (40,41), genetic mutations (42) 
altering miRNAs’ seed sequence, and widespread 
of transcriptional repressions (28). Additionally, 
defects in the key components of miRNA processing 
machinery, such as Drosha, DGCR8, DICER1, TRBP 
and XPO5, were also documented to be involved 
in promoting tumorigenesis (43-47). Moreover, 
miRNAs down regulation have been found to be 
associated with various malignancies, suggesting that 
these miRNAs might be tumor suppressors as their 
exogenous over expression suppresseson cogenesis 
(48). On the other hand, a significant number of 
studies and clinical experiments propose that a subset 
miRNAs may function as oncogenes, annotated as 
“oncomirs”. These miRNAs promote tumorigenesis 
through inhibiting tumor suppressor genes (49) and/
or genes that control cellular differentiation/apoptosis 
(50). These ncRNAs are significantly overexpressed 
in various different cancers (10). 
Evidences from clinical studies, suggest that 
miRNAs play significant roles in the initiation, 
development and metastasis of many human cancers 
(51). Subsequently, deregulated miRNAs with 
expression profiles correlating with the stages of 
cancer, could play potential role as diagnostic and 
prognostic biomarkers of cancer (52,53), and the 
identification of aberrantly expressed miRNA is an 
important milestone towards elucidating miRNA-
mediated oncogenic pathways.
MiR-218: genomic structure and functional 
information
miR-218 precursors originate from two loci 
in human genome. miR-218-1 and miR-218-2 
that generate one identical mature sequence and 
respectively mapped to Slit2 15th intron on 4p15.31 
and Slit3 14th intron on 5q34 chromosomal region. 
SLIT family are membrane-associated glycoproteins 
that bind to a receptor named Roundbout (ROBO) 
Multifunctional role of miR-218 in solid tumors
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and acts as a repulsive mediator preventing the 
crossing of longitudinal axons through the midline of 
the central nervous system of most bilaterian animal 
species during neural and growth development (54, 
55). Slit2 is considered as a tumor suppressor gene due 
to its inactivation in different malignancies including 
breast cancer (56). Slit2 promoter region analysis in 
tumor cells demonstrated that reduced expression 
of Slit2 was correlated with hypermethylation of its 
CpG island in lung, breast, colorectal, glioma, kidney 
and neuroblastoma tumors (54,57-59). Slit2 also 
identified as a conserved target of beta-catenin/Wnt 
signaling pathway (60,61). The CpG island of Slit3 
was also observed to be hypermethylated in glioma 
and breast tumors (57). Intronic location of miR-218 
strongly suggests that precursor sequences of miR-
218 are transcribed together with their host genes, 
and the association between expression patterns 
is validated in various studies (14,62). It was also 
showed that the concomitant transcription pattern 
of miR-218 precursors with their host genes, creates 
a negative feedback loop that regulates Slit-Robo1 
signaling pathway (14).
MiR-218 in solod tumors
MiRNA-218 in esophageal squamous cell 
carcinoma
Esophageal squamous cell carcinoma (ESCC) is 
one of the most prevalent and lethal types of human 
cancers worldwide, particularly common in Asia. 
However, little is known about genetic alterations in 
ESCC. Specific and sensitive biomarkers for early 
detection are required to reduce the high mortality 
and morbidity of the disorder. Tumor-suppressive 
miRNAs seem to be good potential diagnostic and 
therapeutic biomarkers. 
In a study delineating the expression profile of 
several miRNAs in a population of 138 Chinese 
patients newly diagnosed with ESCC,both microarray 
and quantitative RT-PCR data revealed that miR-218 
was significantly under-expressed in tumor tissues in 
comparison with adjacent non-tumor tissues (18). In 
another study, Tian H. et al. showed that the expression 
level of miR-218 was significantly increased in 
ESCC compared with normal adjacent tissue. They 
also found a correlation between its expression level 
with clinicopathological features of samples such as 
tumor stage, metastasis. They also found that induced 
expression of miR-218 significantly reduce migration 
and invasion and proliferation of cancer cells and 
accumulated cells in G0/G1 phase (63).
MiRNA-218 in glioma
Glioma is a common type of primary brain tumor, 
accounting for about 33% of these tumors and the 
most important reason for poor prognosis of this 
cancer is invasive behavior of glioblastoma cells. 
Tumor cells must digest the cellular matrix and filter 
through cell margin to initiate invasion.
Compared with ESCC,larger body of studies has 
investigated the expression patterns of miR-218 in 
Glioma.In YANWEI LIU's study, IHC and FISH 
analysis confirmed the reverse relationship between 
miR-218 with LEF1, a nuclear transducer involved 
in Wnt signaling pathway, and also MMP9 protein 
level (P value =0.021 and 0.015, respectively). MMP 
protein family has crucial roles in invasion regulation 
(64). Studies on up-regulation and inhibition of miR-
218 in glioma cell lines have revealed decreased 
and increased levels of cell invasion, respectively. 
In this study the expression of miR-218 was 
significantly down regulated in glioma tissues 
comparing to normal brain samples (P value =0.009). 
This reduction was greater in III and IV grades in 
comparison with II and III (I/II VS III or IV, P value 
= 0.021 and 0.001). This data shows that miR-218 
expression level may change in different phases 
of cancer, and act as a multifunctional miRNA. 
miR-218 as an intermediary molecule can regulate 
the expression of MMP9 and MMP7 by targeting 
transcription factors involved in the Wnt signaling 
pathway and repress the neural cell proliferation and 
migration in normal levels of oxygen.Wnt signaling 
directly targets the MMP promoters (MMP2/9/7) 
through the LEF/TCF complex and stabilizeB-
catenin protein (65,66). In another study Hongping 
Xia et al. performed luciferase reporter assay and 
argue thatmiR-218 can suppress NF-KP activity by 
targeting ECOP (Epidermal growth factor receptor-
co amplified and over expressed protein) mRNA 
(P value <0.05) and therebysensitize the glioma 
cells for apoptosis (67). Further study conducted by 
Yanyang Tu et al, demonstrated that miR-218 ectopic 
expression significantly diminishes cells invasion 
and proliferation ability in glioma cell lines. They 
also utilized computational strategies to scan for the 
potential targets of miR-218 and validated Bmi1, a 
poly comb group protein, as a putative target for miR-
218 by luciferase reporter technique (P value <0.01) 
(68). Moreover, Ashraf Dallolr et al. results indicate 
that the CpG island in the promoter region of Slit2, 
miR-218-1 precursor host gene, was hypermethylated 
in 71% of glioma cell lines and 59% glioma samples. 
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They also performed loss of heterozygosity analysis 
at a microsatellite marker within Slit2 and showed 
the allele loss in 5% of informative cases.
MiR-218 in cervical cancer
The mortality of cervical cancer is still in high 
levels and most of the patients diagnosed with this 
cancer are at late stages with regional or distant 
metastasis (16). Using miRNA array analyses for 
early and advance staged of cervical cancer tissues, 
in combination with sequencing verification, Long 
Huang et al. identified miR-218 as a discriminator 
for metastatic and non-metastatic cervical tissues 
(P value <0.005) (69). The investigation of miR-
218 effect on radio sensitivity of cervical cancer 
was reported in 2014 by Wang Yuan. According to 
this report, primary cervical cancer cells with low 
levels of miR-218 were less sensitive to radiotherapy 
comparing to those with high level of miR-218 
(R2=0.6471, P value <0.001). The expression level 
of miR-218 was also significantly down regulated in 
cervical cancer samples and cell lines compared with 
normal specimens (P value <0.001). Interestingly, 
over expression of miR-218 enhanced radiation 
induced apoptosis (P value <0.05) (70). Role of 
miR-218 in increasing thesensitivity of CC cells in 
chemotherapy was reported by Jiarui Li et al in 2012. 
According to this data, there is a reverse relationship 
between miR-218 and its target, Rictor (rapamycin-
insensitive companion of mTOR), and the chemo 
sensitivity of CC cells is directly affected by miR-
218 (P value <0.05). In addition, the transfection 
analysis showed that caspase group proteins activity 
is increased by miR-218 over expression. Moreover, 
this microRNA can stimulate apoptosis and decreased 
the proliferation rate and cells viability through AKT-
mTOR signaling pathway (71). Another study by 
Noriko Yamamoto et al. showed that the expression 
level of miR-218 was significantly lower in clinical 
cervical cancer specimens and cell lines than in 
non-cancerous samples (P value=0.0026 and P 
value=0.0001 respectively). In this study, LAMB3, 
an important part of basal lamina, shows a reverse 
relationship with miR-218 at both mRNA and protein 
levels and was introduced as one of the direct targets 
of miR-218 (P value=0.0461). By contrast, the 
expression level of LAMB3 is high in tumor samples 
compared with normal tissue (P value=0.0104). The 
group also introduced Focal adhesion pathway as 
involved signaling pathway in this relationship (72).
MiR-218 in gastric cancer
Gastric cancer (GC) is the second leading cause 
of cancer mortality worldwide (73). Ying Shi et al. 
showed that TFF1 (a member of Trefoil peptide 
family correlated with tumorigenesis) has a potential 
target sequence for miR-218. Western blotting 
and mRNA expression analysis showed opposite 
expression pattern between miR-218 and TFF1, but 
the remarkable result is up regulated expression 
of miR-218-5p in tumor samples compared with 
normal (P value =0.01). Additional analysis showed 
that miR-218-5p can control the progression of GC 
via TFF1 and ERK1/2 dependent pathways (74). In 
contrary to this data, Caiping Gao et al. demonstrated 
that miR-218 expression is significantly lower in 
gastric cancer samples than in their paired normal 
tissues (P value <0.01). They performed a luciferase 
reporter assay to validate the direct targeting of 
ECOP (Epidermal growth factor Co-amplified and 
over expressed Protein) by miR-218 (P value <0.01). 
ECOP is a key regulator of Nf-KB signaling and 
miR-218 inhibits nuclear factor kappa B activation 
by decreasing ECOP (75). In a report by Jun Tie et 
al. the possible process for GC metastasis has been 
described. They demonstrated that the expression 
of two precursor genes for miR-218 (miR-218-
1 and miR-218-2) correlates with expression of 
their host genes (Slit2 and Slit3, respectively). 
Furthermore, they reported thatthe reduction of Slit3 
in GC metastasis cells (compared with normal gastric 
tissue) (P value=0.0001), directly reduces the mature 
miR-218, whereas Slit2 expression has no significant 
effect (P value =0.0772). So it seems that the mature 
form of miR-218 is largely derived from miR-218-
2 precursor in Slit3 host gene. They also evaluated 
ROBO1 mRNA and protein level after miRNA 
over and under expression and reported an inverse 
relationship between miR-218 and ROBO expression 
in the cell (P value <0.05). ROBO can interact with 
Slit and promote tumor angiogenesis and metastasis 
via over expression in cancer cells. They also found 
an association between decreased expression of 
miR-218 in GC and advanced clinical stage, lymph 
node metastasis and poor prognosis (P value<0.05) 
(14). Additionally, serum level of miR-218 in GC 
patients is decreased compared to normal serum (P 
value=0.026). Moreover, serum level of miR-218 
was found to be associated with tumor progression 
features such as metastasis, tumor T stage and grade 
(P value=0.003, P value=0.018 and P value=0.012, 
respectively) (76).
Multifunctional role of miR-218 in solid tumors
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MiR-218 in prostate cancer
Prostate cancer is the most common cancer 
in men and second cause of mortality in western 
countries. In a study, Katia RM Leite et al. attempted 
to compare miR-218 expression level in two sample 
groups of localized high grade prostate carcinoma 
(PC) and metastatic samples. In summary, miR-218 
was invariably highly expressed in all localized high 
grade samples compared to metastatic carcinoma 
samples and PC cell lines (P value<0.001) (26). They 
also demonstrated that miR-218 was over expressed 
in all high grade PC samples compared with benign 
prostate tissue (P value<0.001). Additionally, miR-
218 illustrated a shift in expression between high grade 
PC and localized invasive adenocarcinoma and there 
was a significant loss of miR-218 related to transition 
from localized to metastatic adenocarcinomas (77).
MiR-218 in lung cancer
Lung cancer is one of the leading causes of cancer 
related death in western countries (78). In a study 
conducted by Cathie Carnis et al. it was shown that 
large alterations such as loss of 5q, host region for 
miR-218-2, is common in lung cancer specimens 
(79). Five years later, Morgan R. Davidson et al. for 
the first time identified the location of miR-218 as 
a putative tumor suppressor miRNA in lung cancer 
within a region of genomic loss (4p.15.31 and 5q35.1). 
They also measured the expression level of miR-218 
and its host genes Slit2 and Slit3, in their array CGH 
training set and paired normal lung. In their study, the 
expression of Slit 2 and Slit3 were significantly down 
regulated in tumor samples compared to normal 
tissues (P value<0.001), but there was nosignificant 
relationship between host gene expression level and 
its copy number. MiR-218 was significantly correlated 
only with slit2 but not Slit3 (P value=0.03 and P 
value=0.05, respectively). This may reflect irregular 
production of miR-218 from each loci, alteration of 
miR-218 biogenesis process or existence of separated 
promoters from host genes (80). In combination 
with Real-time PCR and immunohistochemical 
analysis De-Wei Wu et al. identified significant 
reverse relationship between miR-218 and PXN 
(Paxillin), the focal adhesion protein. There was 
a positive correlation between both PXN mRNA 
and protein expression in lung tumors with tumor 
stages (PXN mRNA, P value=0.022; PXN protein, P 
value=0.035). Authors showed that high expression 
of PXN was more prevalent in stage III compared 
to stagesII and I. Conversely, the high expression 
of miR-218 in stage III was less prevalent of that in 
samples at stages II and I. Furthermore, their Kaplan-
Meier analysis showed that the patients with higher 
levels of miR-218 expression have longer average 
months of Overall Survival (OS) and Relapse Free 
Survival (RFS) comparing to the patients with lower 
levels of miR-218 (26.0 months vs. 33.9 months, P 
value =0.014 for OS; 19.3 months vs. 35.4 months, P 
value =0.011 for RFS) (81). One considerable cause 
for lung cancer related morbidity is brain metastasis.
Althoughthe molecular mechanism for brain 
metastasis is not yet clearly understood, it seems that 
there is an important relationship between CDH2 
(N-Cadherin, a mesenchymal marker for epithelial-
mesenchymal transition) and ADAM9 (a type I 
trasmembrane protein) regulation and brain metastasis 
in lung cancer. Yuh-Ping Sher et al. demonstrated that 
ADAM9 expression was significantly up-regulated 
in aggressive lung adenocarcinoma cells and could 
activate the expression of CDH2 (P value<0.05). In 
order to gain molecular insights into the role of miR-
218, above mentioned group performed a luciferase 
assay and western blot analysis to show that CDH2 
is one of target genes for miR-218 and there is a 
reverse relationship between them (P value<0.05). 
Additionally their quantitative RT-PCR results 
showed that in contrast with CDH2, the expression 
of miR-218 was significantly lower in aggressive 
and metastatic lung cancer cells. They examined 
precursor expression levels to investigate which miR-
218 precursor is really deregulated in aggressive lung 
cells. They concluded that down-regulation of mature 
miR-218 expression is directly correlated with Slit2 
host gene as well as miR-218-1 precursor, and there 
was no significant relationship with Slit3 and miR-
218-2 precursor (82). It is known that Slit2 could 
regulate beta-catenin and suppress cell migration 
(83). However it was shown that down-regulation of 
miR-218 was associated with low expression levels 
of Slit3 in gastric and thyroid cancer (23,62). These 
expression alterations between different tissues may 
be due to tissue specificity for miR-218 precursor 
expression. In a MTT assay conducted by Cailian 
Zhang et al. it has been shown that miR-218 over 
expression had no effect on cell growthand viability 
rate inmalignant lung cells (P value<0.01). They 
suggested that miR-218 can play an important role 
in lung metastasis by reduction of migration and 
invasion ability of cancer cells (P value<0.001). They 
also confirmed direct targeting of HMGB1 (High 
Mobility Group Box 1) by miR-218 and an inverse 
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relationship between them (P value<0.05). They 
showed that restored expression of HMGB1 could 
increase cell migration and invasion ability, reduced 
by miR-218 mimics (84).
MiR-218 in colorectal cancer
Colorectal cancer (CRC) is the third major cause 
of cancer related mortality (73). Using Real-time 
PCR analysis Hong Yu et al. showed that miR-218 
expression level is down regulated (in consistent 
with its host genes) in CRC tissue and serum 
samples compared to normal adjacent tissue and 
normal blood (P value <0.001 and  P value <0.05 
respectively). MiR-218 expression with respect to 
Patients characteristics also showed a connection 
between low expression level of miR-218 with high 
TNM stage of samples and worse survival (P=0.038 
and 3.9 *10-4, respectively) (15). Additionally 
Whole-genome loss of heterozigosity analysis 
revealed the association of significant loss of Slit2 
expression with promoter methylation of Slit21 in 
CRC samples (85). Xinqi He et al. identified BMI1 
(polycomb ring finger oncogene-1) as one of the 
potential targets for miR-218. The expression level of 
miR-218 showed significant down regulation in CRC 
samples compared with normal tissue, and BMI1 
expression analysis exhibited a significant inverse 
correlation with miR-218 expression (P value=0.001, 
r=-0.823, P value <0.01). They further revealed that 
miR-218 up-regulatesp 53 protein expression while 
suppressing the expression of BMI1 protein which is 
a downstream target of cell cycle regulator, Cyclin-
Dependent-Kinase 4. This suppression can result 
an increased number of accumulated cells in the G2 
phase (P value=0.01). Unexpectedly, they reported 
that there is not any correlation between miR-218 
expression and clinicopathological characteristics of 
patients such as tumor stage and recurrence (86). 
MiR-218 in pancreatic cancer
Pancreatic cancer is one of the major causes of 
cancer related morbidity worldwide. Ziman Zhu et al. 
reported asignificant relationship between low levels 
of miR-218 in PDAC cells and tissue samples, and 
poor tumor differentiation, advanced tumor stage, 
higher incidence of lymph node metastasis, tumor 
recurrence and lower 5 year RFS (P value=0.002, 
0.001, 0.002, 0.010 and 0.009 respectively) (87). 
In another research, CHI HAN LI et al. performed 
quantitative RT-PCR and immunohistochemistry 
analysis and showed that levels of miR-218 is 
significantly lower in primary PDAC tumor samples 
compared with paired adjacent normal tissue (P 
value <0.0001). Additional experiments approved 
that EZH2 (Enhancer of Zeste Homolog2) is capable 
to silence miR-218 expression by histon methylation 
and heterochromatin modification of its promoter. 
As miR-218 target genes, highly expressed levels 
of UTG8 (UDP glycosyltransferase) and VOPP1 
(over expressed in cancer, prosurvival protein) 
were also observed to be significantly associated 
with dysregulation of EZH2-miR-218 pathway and 
increased cell aggressiveness. They also evaluated 
Slit2 and Slit3 levels, and showed that only 
expression of Slit3, not Slit2 was low in pancreas 
cancer cell lines (P value <0.05). Conclusively, they 
reported that levels of mature miR-218 were totally 
associated with miR-218-2 precursor and Slit3 host 
gene expression and promoter methylation (P value 
<0.05) (88).
MiR-218 in hepatocellular carcinoma
Hepatocellular carcinoma is the fifth most 
common malignancy worldwide (89). Zhong-Di 
Xiao et al. investigated the molecular mechanism of 
miR-218 regulatory pathway in human hepatocellular 
carcinoma (HCC), and showed that tumorigenesis 
related proteins cyclin D1 and p21, together with 
PTEN/AKT/PI3K signaling pathway are connected to 
miR-218. Additionally, they suggested that due to the 
reverse correlation between miR-218 and HOXA10, 
this protein is directly associated with miR-218 
in regulating PTEN/AKT/PI3K pathway in HCC 
cells. They also reported that miR-218 expression is 
down regulated in HCC cell lines and tissue samples 
compared with normal cells and paired tissues (P 
value <0.05) (90). Down regulation of miR-218 in 
HCC cell lines and tissue samples was also reported 
by Chengjun Sui et al. (Pvalue <0.05). They combined 
bioinformatics analysis and functional assays to 
predict and confirm that miR-218 is directly targeting 
RET (a transmembrane receptor-type tyrosin kinase 
and functions as proto-oncogene) in HCC cells. 
They showed that the protein level of RET was also 
up regulated through miR-218 transfection (P value 
<0.05) that could reverse the anti-proliferative effect 
of miR-218 upregulation, whereas the expression 
of PTEN (phosphatase and tensin homolog deleted 
on chromosome 10, a tumor suppressor gene and 
targets of mTOR signaling pathway in cancer) was 
significantly down regulated (P value <0.05) (91). 
Multifunctional role of miR-218 in solid tumors
Genetics in the 3rd  Millennium, Vol. 14, No.2  Spring  20164284
D
ow
nl
oa
de
d 
fro
m
 g
3m
.ir
 a
t 1
3:
42
 +
04
30
 o
n 
W
ed
ne
sd
ay
 J
ul
y 
5t
h 
20
17
MiR-218 in thyroid cancer
Thyroid cancer is the most common malignancy 
of endocrine system and its overall incidence and 
mortality is increasing rapidly in recent years 
worldwide (92). In a study by Hongyu Guan et 
al. statistical analysis of expression levels of pre-
miR-218-1 and Slit2, pre-miR-218-2 and Slit3 
showed that microRNA transcripts positively 
correlated with their related host genes (P value 
<0.05). QRT-PCR analysis also showed that miR-
218 expression is down regulated in thyroid cancer 
lesions compared to normal tissue (P value <0.05), 
but it wasn’t observed any association between down 
regulation of miR-218 and the degree of malignancy 
phenotype. Moreover, they suggested that expression 
levels of mature miR-218 in thyroid cancer attributes 
to miR-218-2 precursor and Slit3 host gene (P 
value <0.001); Whereas, no significant difference 
was observed in Slit2 expression level in thyroid 
cancer specimens compare with normal tissue (P 
value =0.995). According to this data and additional 
analysis, it seems that miR-218-2 and Slit3 have a 
functional relevance in invasion and proliferation of 
thyroid cancer cells. Furthermore, bioinformatics and 
functional analysis demonstrated two direct targets 
of miR-218-2, PDGFRA (platelet-derived growth 
factor receptor, which is a cell surface tyrosine 
kinase receptor for members of the platelet-derived 
growth factor family) and PLCG1 (phospholipase 
C, which plays an important role in the intracellular 
transduction of receptor-mediated tyrosine kinase 
activators) which both of them are involved in cancer 
cell invasion and mitosis (62).
MiR-218 in melanoma
The most fatal form of skin cancer is cotaneous 
melanoma, and its incidence has increased recently 
worldwide (93). In a study, Hun-Way Huang et 
al. investigated the expression levels of miR-218 
precursors and HIF1A (hypoxia inducible factor 
1 alpha) and found a positive correlation between 
miR-218 and HIF1A over expression in melanoma 
cell lines (P value<0.05). Moreover, the expression 
of miR-218 was significantly decreased by HIF1A 
suppression (P value<0.005). Expressional analysis 
for Precursor sequences also showed that there was 
specificity for the pri-miR-218-2 locus on Slit3, 
because the down regulated sequence of miR-218 
is attributed to pri-miR-218-2 which was decreased 
by 70%, while pri-miR-218-1 was unaffected (94). 
Expressional analysis conducted by Yanping Wei 
et al. showed that the expression levels of miR-
218 were down regulated in primary and metastatic 
melanoma samples and cell lines compared with 
normalspecimens (P value<0.05). Moreover CIP2A 
(cancerous inhibitors of protein phosphatase 2A,) 
and BMI1, two cellular oncogenes, were in a reverse 
relationship with miR-218 expression (P value <0.05) 
and according to luciferase assay data, they are 
targeted by miR-218 directly in their 3-UTR region. 
Additional cell line experiments showed that miR-
218 inhibited cell proliferation and arrest cell cycle in 
G0/G1 phase and significantly reduced the percentage 
of cells in S phase (P value <0.05) (95). Differential 
expression of miR-218 in acral melanoma compared 
to non-acral melanoma makes it a possible biomarker 
to distinguish between melanoma subtypes (96). 
MiR-218 in renal carcinoma 
Renal cell carcinoma (RCC) is the most common 
cancer of the adult kidney (97). Renal carcinoma 
tumors originate from kidney parenchyma and the 
incidence of this cancer is low in Asia and South 
America in contrast with Europe and North America 
(98). According to luciferase reporter assay performed 
by Takeshi Yamasaki et al. CAV2 (Caveolin2) a gene 
involved in Focal adhesion pathway, has an actual 
target region in its 3-UTR for miR-218. Expressional 
experiments also showed that there was an inverse 
correlation between miR-218 and CAV2 expression 
levels (r=-0.58, P value<0.0001). MiR-218 was 
significantly down regulated in RCC samples and 
cell lines compared to normal (P value<0.0001) 
(99). Slit2 promoter methylation has been previously 
described by Ashrad Dallol et al. in RCC samples 
and cell lines. However it seems that the original 
resource of mature form of miR-218 is Slit2 host 
gene and miR-218-1 precursor in RCC considering 
consistent expression levels of this miRAN with 
Slit2 host gene (59). In addition, tumor suppressory 
roles of miR-218 in RCC cell lineshas been revealed 
through functional screening analysis conducted by 
Hideo Hidaka et al (100).
MiR-218 in nasopharyngeal carcinoma (NPC)
Nasopharyngeal carcinoma is associated with 
Epstein-Bar virus and has a high incidence in East 
Asia and Africa. In the only study that was published 
regarding the expression pattern of miR-218 in 
NPC tumors, it was reported that the expression of 
miR-218 and its host genes are consistently down 
regulated in NPC samples and cell lines compared 
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with normal cells (P value<0.0005). Additional 
investigations indicated that epigenetic modifications 
such as hypermethylation of Slit3 and Slit3 host genes 
promoter’s leads to under expression of Slit2 and Slit3 
genes and subsequently miR-218 down-regulation in 
different malignancies. Moreover, luciferase reporter 
assay analysis also resulted in identification of direct 
interaction between miR-218 and 3-UTR region of 
BIRC5, ROBO1, and GJA1mRNAs. ROBO1 has 
an inverse correlation with patient’s OS (overall 
survival) and (23) plays important role in cell 
invasion and migration (55,101).
MiR-218 in medulloblastoma
Medulloblastoma (MB) is one of the most common 
forms of brain and cerebellar related tumors in 
children (102). High throughput miRNA microarray 
and RT-PCR expressional analysis performed by 
Liu Wei et al. validated down regulation of miR-
218 expression levels in primary MB specimens 
compared to normal tissue (P value=0.004) (103). 
In a study conducted by SujathaVenkataraman et al. 
the expression of miR-218 was observed to be down 
regulated in MB cell lines and samples compared 
with normal cells (P value<0.0001). Additional in 
vitro experiments also showed that induced over 
expression of miR-218 reduces malignant features 
of medulloblastoma cells. Moreover, an inverse 
significant correlation was observed between miR-
218 with CDK6 (cyclin dependent kinase 6), RICTOR 
(rapamycin independent companion of mTOR) and 
CTSB (cathepsin B) expression levels (104). In 
another study,Jipeng Shi et al assessed and validated 
reverse relationship between miR-218 and SH3GL1 
in MB cell lines and samples by qRT-PCR, luciferase 
reporter assay and western blotting analysis. Authors 
performed additional analyses to clarify miR-218 and 
SH3GL1 associated signaling pathways in MB. They 
revealed that miR-218 mediates SH3GL1 via MAPK 
signaling pathway (P value <0.05) (105).
 
MiR-218 in bladder cancer
Bladder cancer (BC) is the second most common 
genitourinary related cancer (106). To appraise 
genomic aberrations in BC, R Matsuda et al. 
performed CGH-array analysis on BC cell lines. They 
reported that one of the loci which most frequently 
undergoes genetic lostin BC is on chromosome 4p 
where miR-218-1 Precursor is located (107). In 
another study, Shuichi Tatarano et al focused on 
chromosome 4p15.31 and miRNAs located in this 
region. They validated CGH-array data by evaluating 
the expression level of miR-218 and found a 
significant down regulation in all four BC cell lines. 
Additional gain of function studies also showed 
significant cell proliferation inhibition in miR-218 
transfectant cell lines (P value<0.05). They also 
predicted one of potential targets of miR-218 named 
TMX1 (25). Additional investigations showed that 
there is a reverse correlation between miR-218 and 
LASP1 (LIM and SH3 protein 1) mRNA and protein 
levels,  introducing LASP1 as another target of miR-
218 (108).
 
MiR-218 in breast cancer 
Breast cancer is the most common diagnosed 
cancer and major cause of cancer related morbidity in 
women (109). Aoife J Lowery et al by using artificial 
neural networks (ANN) combined with miRNA 
expression profiling and qRT-PCR analysis, showed 
that miR-218 has a distinct expression pattern for 
discriminating between ER-positive and ER-negative 
breast tumors with accuracy of 100% (110). Qiaoyan 
Li et al demonstrated that expression of HoxB3 
(highly conserved subgroup of the homeobox family) 
is strongly and reversely in correlation with miR-218 
and this miRNA works synergistically with miR-7 to 
target HoxB3 3'-UTR. They also constructed stable 
miR-218 expressing breast cancer cell lines and 
showed that in these cells tumor suppressor genes, 
RASSF1A (RAS associated domain family 1A) and 
CLDN6 (Claudin 6) mRNA levels are significantly 
increased, resulting in inhibited cell cycle and colony 
formation of breast cancer cells (P value <0.05) (111). 
According to Mohammad Q. Hassan et al study, 
miR-218 directly regulates osteogenesis-related 
signaling pathways such as Wnt and BMP and may 
mediate progression of osteogenesis pathways. By 
using luciferase reporter assay analysis during bone 
formation, they validated fourWnt signaling pathway 
negative regulators as miR-218 targets namely, 
Tob1, Dkk2, sfrp2 and Sost. They also found that 
induced expression of miR-218 actively increased 
endogenous Tcf-1 and Lef-1 expression levels and 
endogenous Wnt was highly activated in metastatic 
breast cell lines. Expressional analysis showed that 
miR-218 expression is low in mammary epithelial 
normal cells while it is increased by 10 fold in highly 
metastatic cells. Conclusively, they found that miR-
218 induces expression of Wnt activators like TCF-
1, B- catenin, Runx2 by suppressing expression of 
inhibitors such as axin2 (112). In another study, Xiao 
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He et al. showed that miR-218 is down regulated 
in cisplatin-resistant breast cancer cells. MTS and 
colony-forming assays represented significant 
increase in IC50 in mir-218 transfectant breast cancer 
cell lines after cisplatin treatment. They also validated 
targeting of BRCA1 (breast cancer 1) 3-UTR, DNA 
repair gene, by miR-218. Diverse strategies was 
used in this study to show that low expression of 
miR-218 and high expression of its target, BRCA1, 
are associated with cisplatin resistance and cell 
viability in breast cancer cell lines (113). Tatiana 
Y Prudnikova et al investigated the correlation 
between miR-218 and GLCE (D-glucuronyl C5-
epimerase) tumor suppressor gene, in breast cancer 
cells. They observed a significant decrease of miR-
218 expression level in primary breast tumors. They 
also found an inverse correlation between miR-218 
and GLCE protein levels but not mRNA, indicating 
possibly incomplete interaction between miR-218 
and GLCE mRNA which only results in suppression 
of mRNA translation (114).
Discussion and Conclusion:
First discovered in 2012 by Sempere LF et al (13), 
miR-218 has been implicated to prevention of various 
types of cancers as a tumor suppressor miRNA; 
however, further studies argued that It can also have 
other regulatory functions in cancerous cells including 
oncogenic role as its over-expression was observed in 
some other types of cancer or specific conditions such 
as higher grades and stages of the disease (26,63,74, 
77,110). Despite such controversial observations, 
several studies have proposed the association of miR-
218 expression perturbation with poor prognosis in 
some malignancies (14-16,69).
Here, an attempt was made to decipher the 
precise molecular role of miR-218 in various solid 
tumors. To do so, we reviewed up to 124 original 
articles regarding to functional analysis of miR-218 
during tumorigenesis or development of different 
solid malignancies. Many of these studies were 
aimed to investigate expression level of miR-218 in 
corresponding cell lines or tumor tissues accompanied 
by experimentally validated methods in order to 
confirm dysregulated miR-218 target genes and 
signaling pathways. However, we also reviewed the 
studies aiming to only examine expression pattern of 
miR-218 in diverse biological samples derived from 
various solid malignancies.
Table 1 and figure 1 represent a brief summary 
of miR-218 functions in different solid tumors. As 
it is evident, majority of studies propose the tumor 
suppressor role of miR-218 during tumorigenesis 
of different solid tumors considering the fact that 
it is significantly down-regulated in tumor tissues 
in comparison with normal healthy specimens. In 
addition, in all of these studies it is shown that in-
vitro ectopic over-expression of miR-218 contributes 
to suppression of cell proliferation, metastasis and 
invasion by targeting various oncogenic proteins 
(Figure 1). By contrast, two studies represent 
oncogenic role of miR-218 during tumorigenesis of 
cancerous cells in Gastric cancer and Esophageal 
Squamous Cell Carcinoma by providing concrete 
in-vivo and in-vitro evidence (63,74). These studies 
demonstrated that miR-218 is up-regulated in tumor 
tissues compared with normal tissues. Furthermore, 
functional analysis revealed that ectopic induction of 
miR-218 in cancerous cell lines results in increased 
cell proliferation by targeting TFF1 protein (74) 
(Figure 1). In consistent with these data, comparison 
of miR-218 expression level among tumor tissues 
with different grades and metastatic stages, showed 
that expression of miR-218 is elevated in first and 
middle grades compared with higher grades where 
cancerous cells acquire metastatic and invasive 
characteristics (26,77,110). Likewise, recently 
we analyzed expression level of miR-218 in 33 
pairs of breast tumors and adjacent normal tissues. 
Our results revealed up-regulation of miR-218 in 
cancerous tissues compared with normal adjacent 
tissue; however, it was significantly down-regulated 
in Lymph node metastatic (LNM) positive compared 
with LNM negative samples (F Ahmadinejad et al, 
Shahrekord University of Medical Sciences, ahead 
of print). Finally, another set of studies attributed 
different functions to miR-218 in cancerous cells, 
represented its role in chemo sensitivity to Cisplatin 
and promoting osteomimetic properties in metastatic 
cancer cell by targeting BRCA1 and Sclerostin/
Dikkopf2, respectively (112, 113) (Figure1).
Taken together, the studies highlighted in current 
review clearly indicate that miR-218 act as a multi-
functional regulator of cellular processes in cancerous 
cells and its expression perturbation could be 
representative of various states of the solid tumors. In 
fact, considering cancer as a complex and multi-state 
disease, it seems that miR-218 function as a Double-
edge sword in solid tumors where despite its tumor 
suppressive role, its expression at a basic level is 
required for regulation of cancerous cell proliferation 
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and differentiation, particularly at early and middle 
states of the disease. Hence, it seems of great 
importance to check patient’s clinico-pathological 
characteristics (such as stage, tumor grade, LNM 
status and so forth) before interpreting miR-218 
expression level as a diagnostic or prognostic factor.
Figure 1: Various functions of miR-218 in solid tumor cells. By targeting different set of target genes in various cancerous cells, miR-
218 participates in diverse functions, including Regulation of Cisplatin chemosensitivity (A), Inhibition of cancer cell proliferation, 
migration, and invasion (B), Increasing and regulation of cancer cell proliferation and differentiation (C), and promoting osteo-mimetic 
properties in metastatic cancer cells (D). 
BRCA1: Breast Cancer1, GJA1: Gap Junction protein Alpha1, CDK6: Cyclin Dependent Kinase6, RICTOR: RPTOR independent 
companion of MTOR, complex 2, HOXB3: Homeobox B3, HMGB1: High Mobility Group Box1, PLCG1: Phospholipase C-Gamma 1, 
GLCE: Glucuronic Acid Epimerase, ECOP: EGFR-coamplified and overexpressed protein, CAV2: Caveolin 2, PXN: Paxillin, BMI1: 
B lymphoma Mo-MLV insertion region 1 homolog, RET: receptor tyrosine kinase, ROBO1: Roundabout, Axon Guidance Receptor, 
Homolog 1, CDH2: Cadherin 2, LAMB3: Laminin subunit beta-3, PDGFRA: platelet-derived growth factor receptor alpha, BIRC5: 
Baculoviral IAP Repeat Containing 5, CTSB: Cathepsin B, SH3GL1: SH3-Domain GRB2-Like 1, LASP1: LIM And SH3 Protein 1. 
TFF1: Trefoil Factor 1, DICKKOPF2: Dickkopf-related protein 2.         : induction,         : inhibition.  
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Table 1: Br ief summary of miR-218 functions in different solid tumors.
Reference Clinopathological
categorizaƟon
 Targets and
signaling pathways
 DeregulaƟon direcƟon  / overall  funcƟon
of miR-218
Sample typeStudy typeNum
 T
yp
e 
of
ca
nc
er
 Lymph
node status
TNM
Stage
(111)NegaƟveStage 1 or 2A-Up-regulated in ER+Vs ER- tumors ER
 +/ ER – fresh tumor
samples
 Case-control
expression study
1
Br
ea
st
 C
an
ce
r
(112)--HoxB3 Act as a Tumor suppressor  Induces RASSF1Aand Claudin-6
 Stable miR-218 expressing
breast cancer cell lines
 Cell culture
 funcƟonal analysis
study
2
(113)--
 SclerosƟn,
Dickkopf2, Frizzled-
 related protein2
 (Wnt signaling
pathway inhibitors)
 Inducer of osteogenic lineage commitment
and progression
 promotes osteomimeƟc properƟes in
metastaƟc breast cancer cells
 MC3T3-E1
 osteoprogenitors Bone
 marrow stromal cells
MCF10A epithelial cells
 Cell culture
 funcƟonal analysis
study
3
(114)--BRCA1Ectopic overexpression Rescued cisplaƟn-resistance in breast cancer cells
MCF-7 cell line, cisplaƟn-
resistant cell line (MCF-7/
DDP)
 Cell culture
 funcƟonal analysis
study
4
(115)ND
 Majority of
 samples were
Stage 2
GLCE
 Down regulated in Primary breast tumors
 VS normal
Ɵssues
Act as tumor suppressor
 Primary breast cancer
 Tissue Vs
normal breast Ɵssue
MCF7 cell line
 Case-control
expressiona
 l  and cell culture
 funcƟonal analysis
study
5
(81)NDND-
Down regulated in Primary NSCLCs tumors
Act as tumor suppressor
 primary non-small cell
lung cancers
 (NSCLCs) VS Normal lung
Ɵssues
 Case-control
expressional study1
Lu
ng
 C
an
ce
r
(82)ND
40.3% stage I
20.2% stage II
39.5% Stage III
PXN
Down regulated in primary tumors
 Act as a tumor progression and metastasis
suppressor
 primary lung cancer VS
normal Ɵssue
Lung cancer cell lines
 Case-control
 expressional
 and cell culture
 funcƟonal
analysis  study
2
(83)--CDH2
 Down regulated in Non invasive VS invasive
cells
Act as a metastasis and invasion suppressor
 Non invasive VS invasive
lung
 adenocarcinoma cell lines
 Cell culture
expressional
 and  funcƟonal
 analysis
study
3
(85)--HMGB1Act as a metastaƟc and invasion suppressor
 Human lung cancer cell
lines, A549
 and H1299
 Cell culture
 funcƟonal
analysis study
4
(27)--- Up-regulated in High grade Ɵssue VsmetastaƟc carcinoma
Act as a metastasis suppressor
 localized high grade
 prostate
 carcinoma staged pT3 Vs
 metastaƟc,
 androgen-independent
 prostate
carcinoma
 Case-control
 expressional
study
1
Pr
os
ta
te
 C
an
ce
r
(78)---
 Up-regulated in High grade Vs local invasive
and
metastaƟc samples
Act as a metastaƟc suppressor
 high grade prostate Vs
local invasive
 VS metastaƟc Ɵssue
samples
 Case-control
expressional
study
2
(18)NDND-
 Down-regulated in tumor Ɵssue VS adjacent
normal Ɵssue
Act as a tumor suppressor
 Primary ESCC tumor
Ɵssues VS
  adjacent non-tumor
Ɵssues
 Case-control
 expressional
study
1
 E
so
ph
ag
ea
l S
qu
am
ou
s C
el
l
Ca
rc
in
om
a
(64)NDND-
 Up-regulated in tumor Ɵssue VS adjacent
normal Ɵssue
Act as a tumor suppressor
 Primary ESCC Ɵssues VS
matched
non-tumor Ɵssues
 Case-control
expressional
 and Cell culture
funcƟonal
analysis study
2
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(68)--
ECOP
 NF-kB signaling
pathway
 Down regulated in Glioma cell lines VS Glia
cells
Act as a tumor suppressor
 Human glioma cell lines
(U87, U118,
 U138, U373, SW1088,
SW1783) VS
immortalized glial cells
 Cell culture
funcƟonal
analysis study
1
Gl
io
m
a
(69)--Bmi1
 prevents migraƟon, invasion, proliferaƟon of
Glioma Cells
Act as a tumor suppressor
Human glioma cell lines
 Cell culture
funcƟonal
analysis study
2
(70)
 31%
posiƟve
and 68%
negaƟve
 Staged 1A
and 2-
 Its downregulaƟon correlates with metastaƟc
parameters
Act as a tumor suppressor
Formalin-fixed paraﬃn-
embedded
 Ɵssues (FFPETs)
 Case-control
expressional
 study
1
Ce
rv
ic
al
 C
an
ce
r
(71)NDND-
 Down-regulated in cancer Ɵssue VS normal
samples
Promotes radio-sensiƟvity in paƟents
 fresh cervical cancer VS
non-
cancerous cervix Ɵssues
tumor dereived cell culture
 Case-control
expressional
 and Cell culture
funcƟonal
analysis  study
2
(72)---
 Overexpression of miR-218 reduced the
proliferaƟon of the
 human cervical cancer and increased
chemosensiƟvity to
cisplaƟn
Act as a tumor suppressor
 human cervical cancer cell
line HeLa
 Cell culture
expressional
study
3
(73)--
LAMB3
Down-regulated in SCC VS non-cancerous
Inhibits proliferaƟon, migraƟon and invasion
 primary cervical SCC
specimens VSnon-
cancerous specimens
Cervical SCC cell lines
 Case-control
expressional and
 Cell culture
 funcƟonal
analysis  study
4
(75)--
TFF1
 Erk1/2 signaling
pathway
 Up-regulated in tumor Ɵssue VS normal
Ɵssue
Act as an oncogen
Increases and regulates proliferaƟon
 GC paƟent tumor lesions
 VS normal
 paracancerous Ɵssue
samples
 BGC-823 and SCG-7901
cell lines
 Case – control
 expressional  and
 cell
 culture funcƟonal
 analysis
study
1
Ga
st
ric
 C
an
ce
r
(77)NDND- Down-regulated in PaƟents VS Healthyspecimens
More reducƟon in paƟents with metastasis
 serum of gastric cancer
 paƟents VS
healthy individuals
 Case-control
expressional
 study
2
(15)
 55%
negaƟve
 45%
posiƟve
12.7% staged I
 38.6%
staged II
 42.9% staged
III
 5.5% staged
IV
-
 Down-regulated in paƟents VS healthy
specimens
 DiagnosƟc and prognosƟc Biomarker of
Lymph node metastasis
 CRC Ɵssue and serum
sample VS
 normal adjacent Ɵssue and
normal
serum
 Case-control
expressional
 study
1
Co
lo
re
ct
al
 ca
nc
er
(87)--
                 BMI-1
 Down-regulated in tumor Ɵssue VS normal
adjacent
ƟssueAct as a tumor suppressor
 Ectopic expression induces apoptosis and
 inhibit cell proliferaƟon and promotes cell
cycle arrest at G2
 primary tumor VS adjacent
non-
tumor Ɵssue
 Colon cancer cell lines
 HCT116, HT29, SW620
and LoVo
 Case- control
 expressional
  and cell culture
funcƟonal
 analysis study
2
(88)NANA-
 Down regulated in tumor Ɵssue VS normal
Ɵssue
 Reduced expression was correlated with
 poor tumor
 diﬀerenƟaƟon, advanced tumor stage, higher
 incidence of
 lymph node metastasis, and tumor
recurrence
 PancreaƟc ductal
 adenocarcinimat
 Ɵssues VS normal
pancreaƟc Ɵssues
 Case-control
expressional
 study
1
Pa
nc
re
aƟ
c 
ca
nc
er
(89)NDNDUDP-glycosyltransferase
 Down-regulated in Tumor Ɵssue Vs normal
Ɵssue
 Ectopic overexpression reduced proliferaƟon
and tumor formaƟon and metastasis in nude
 primary PDAC tumor VS
adjacent
 non-tumor Ɵssue
SW1990 cell line
 Case-control
expressional
  and cell culture
 funcƟonal
study
2
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(91)--
HoxA10 through
  PTEN/AKT/PI3K
pathway
Act as Tumor suppressor
 Ectopic overexpression decreased cell
proliferaƟon
HCC cell lines
 Cell culture
 funcƟonal
study
1
He
pa
to
ce
llu
la
r c
ar
ci
no
m
a
(92)NDNDRET
 Down-regulated in tumor Ɵssues Vs normal
Ɵssues
 Ectopic overexpression decreased cell
proliferaƟon andinvasion capability
 primary HCC Ɵssues Vs
adjacent
   non-carcinoma Ɵssues
 HCC cell lines MHCC97L
and Huh7
 Case-control
expressional
 and cell culture
funcƟonal
study
2
(63)NDNDPDGFRA and PLCG1
 Down-regulated in tumor Ɵssue Vs normal
Ɵssues
 Ectopic overexpression reduced the rate of
proliferaƟon,
  invasiveness and migraƟon
 normal Vs neoplasƟc
human thyroid
 Ɵssues
 Human thyroid cancer
cell lines
 WRO and 8305C
 Case-control
 expressional
study
1
Th
yr
oi
d 
ca
nc
er
(96)NDNDCIP2A and BMI1
 Down-regulated in melanoma Vs normal
Ɵssue
 Ectopic overexpression reduced proliferaƟon,
 migraƟon,
and invasion
 Melanoma Ɵssues Vs
normal Ɵssue
 Melanoma cell lines A375
and SK-
MEL-2
 Case-control
expressional
  and cell culture
funcƟonal
 analysis study
1
M
el
an
om
a
(100)--CAV2
 Ectopic overexpression inhibited
 proliferaƟon, migraƟon
and invasion
 A498 and 786-O renal cell
carcinoma
 cell lines
 Cell culture
 funcƟonal
analysis study
1
Re
na
l c
el
l c
ar
ci
no
m
a
(101)---
Down-regulated in Cancer Vs normal Ɵssue
Ectopic overexpression inhibited proliferaƟon
Cancer Vs adjacent non-
 cancerous
Ɵssue
RCC cell lines: A498, 786-
O, ACHN
 and caki-2
 Case-control
expressional
  and cell culture
 funcƟonal
analysis study
2
(23)NDND
 ROBO1, survivin
(BIRC5)
 and connexin43
(GJA1)
Down-regulated  in cancer Vs normal Ɵssue
Exogenous expression delayed tumor growth
 Primary Nasopharayngeal
carcinoma
 Ɵssue Vs normal Ɵssue
 Nasopharayngeal
carcinoma cell
 lines
 Case-control
expressional
  and cell culture
funcƟonal
 analysis study
1
 n
as
op
ha
ry
ng
ea
l
ca
rc
in
om
a 
(N
PC
)
(104)NDND-Down-regulated in Cancer Vs normal Ɵssue
 human primary
medulloblastoma
 Ɵssue Vs on-tumorous
cerebellum
Ɵssues
 Case-control
 expressional
study
1
m
ed
ul
lo
bl
as
to
m
a
(105)NDND CDK6, RICTOR, andCTSB (cathepsin B)
Down-regulated in Cancer Vs normal Ɵssue
  Ectopic overexpression decreased
 medulloblastoma cell
 growth, cell colony formaƟon, cell migraƟon,
invasion
 human primary
medulloblastoma
  Ɵssue Vs on-tumorous
cerebellum
 Ɵssues
 Case-control
 expressional
  and Cell culture
 funcƟonal analysis
study
2
(106)--SH3GL1
 Down-regulated in cancerous cell lines Vs
normal cell lines
 Ectopic overexpression suppressed cell
growth, migraƟon
 and invasion
 Medulloblastoma cell lines
 Daoy,
 D458, PFSK and UW228
Vs normal
 cerebellum
 Cell culture
expressional
  and  funcƟonal
 analysis
 study
3
(25)NDNDND
 Down-regulated in cancerous Ɵssues Vs
normal Ɵssues
 Ectopic overexpression inhibited BC cell
proliferaƟon, migraƟon and invasion.
 cancerous Vs normal
bladder epithelium
Human BC cell
 Lines: T24 , UMUC, kk47,
BOY.
 Case-control
expressional
  and Cell culture
 funcƟonal analysis
study
1
Bl
ad
de
r c
an
ce
r
(109)--LASP1Ectopic expression inhibited cell viability
Human BC cell
Lines
 Cell culture
 funcƟonal
analysis study
2
 (ND = Not determined)
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